Page 98 - Demo

Chapter 596(n=7), miR-141-3p (n=2) and miR-218-5p (n=2) were measured in GC samples and miR-200c-3p (n=5), miR-375 (n=5), miR-21-5p (n=6) and miR-148a-3p (n=6) were measured in EC samples. No significant change in the expression of the measured miRNAs was observed between baseline and follow-up samples of patients with a favorable PFS compared with poor PFS, based on the median PFS (data not shown). Differences in miR-141-3p and miR-218-5p expression in GC samples could not be analyzed due to the small sample size. miRNA relation with response to treatment in plasma of patients with GC and EC For each miRNA the expression levels between patients with partial response (PR), or no response (stable disease, SD/progressive disease, PD) were compared. Three patients did not receive chemotherapy after randomization (1GC; 2EC). The baseline samples of these patients are not included in the response analysis but were included in the intention to treat analysis for PFS and OS. In GC no significant differences in ci-miRNA expression levels were observed between patients with PR or no response (SD/PD) (miR-200c-3p, n=4 vs. 5, p=1.0; miR-146a-5p, n=4 vs. 5, p=0.7; miR-141-3p, n=2 vs. 4, p=0.1; miR-218-5p, n=2 vs. 3, p=0.9). Also, in patients with EC (AC and ESCC) no significant differences in ci-miRNA expression levels were observed between patients with PR or no response (SD/PD) (miR-200c-3p, n=5 vs. 19, p=0.8; miR-21-5p, n=5 vs. 19, p=0.2; miR-375, n=5 vs. 19, p=0.4; miR148a-3p, n=5 vs. 18, p=0.4), (data not shown). None of the patients had a complete response (CR). miRNA expression and clinical benefit from palliative chemotherapy The expression of miR-200c-3p in patients with AC primary from GC and EC origin was not different between patients with (n=14) or without (n=19) clinical benefit of palliative chemotherapy (n=33; HR=0.8 95% CI: 0.4 to 1.6, p= 0.6). Clinical benefit was defined as PR, CR or SD after 6 cycles vs patients with PD during chemotherapy.Vitamin supplementation and miRNA expression For the conducted clinical trial patients were randomized into treatment groups with or without vitamin supplementation. Differences in miRNA expression of the follow-up samples were compared between patients treated with chemotherapy supplemented with or without vitamin. Only for miR-146a-5p a trend towards a significant decreased miR-146a-5p expression in patients who were randomized